Tamoxifen for early breast cancer: an overview of the randomised trials

For trials of 1 year, 2 years, and about 5 years of adjuvant tamoxifen, the proportional recurrence reductions produced among these 30 000 women during about 10 years of follow-up were 21%, 29%, and 47%, respectively, with a highly significant trend towards greater effect with longer treatment

2002

Scholarcy highlights

  • The overall effects of tamoxifen appeared to be small, and subsequent analyses of recurrence and total mortality are restricted to the remaining women
  • For trials of 1 year, 2 years, and about 5 years of adjuvant tamoxifen, the proportional recurrence reductions produced among these 30 000 women during about 10 years of follow-up were 21%, 29%, and 47%, respectively, with a highly significant trend towards greater effect with longer treatment
  • The corresponding proportional mortality reductions were 12%, 17%, and 26%, respectively, and again the test for trend was significant
  • The proportional mortality reductions were similar for women with node-positive and node-negative disease, but the absolute mortality reductions were greater in node-positive women
  • In terms of other outcomes among all women studied, the proportional reductions in contralateral breast cancer were 13%, 26%, and 47% in the trials of 1, 2, or about 5 years of adjuvant tamoxifen
  • Some years of adjuvant tamoxifen treatment substantially improves the 10-year survival of women with ER-positive tumours and of women whose tumours are of unknown ER status, with the proportional reductions in breast cancer recurrence and in mortality appearing to be largely unaffected by other patient characteristics or treatments

Need more features? Save interactive summary cards to your Scholarcy Library.